# eleva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eleva

- Industry: Pharmaceuticals
- Headquarters: Freiburg im Breisgau, Germany
- Website: www.elevabiologics.com
- Total disclosed funding: $7.1M
- Latest round: Series B (Nov 25, 2006)
- Investors on record: 4

## About

Eleva GmbH is a biopharmaceutical company focused on developing innovative biologic therapies aimed at treating complex medical conditions, particularly orphan diseases, through advanced manufacturing techniques and cutting-edge research.Founded in 1999 and headquartered in Freiburg im Breisgau, Germany, Eleva Biologics specializes in biologic therapies. The company raised EUR 60 million in funding from Zukunftsfonds Heilbronn in January 2021, marking a significant investment milestone.Eleva Biologics specializes in developing innovative biologic therapies that address complex medical needs, particularly in the realm of orphan diseases. The company’s flagship product, Factor H (CPV-104), targets complement disorders and represents a significant advancement in the treatment landscape for patients with these rare conditions. Eleva's transformative manufacturing platform utilizes moss technology to produce biologics that are traditionally challenging to manufacture, enhancing the accessibility and efficacy of these critical therapies. Their product offerings cater primarily to healthcare institutions, specialty pharmacies, and research organizations, with a focus on markets in Europe and North America. Through these products, Eleva aims to deliver unique therapeutic solutions that improve patient outcomes and address unmet medical needs.In 2022, Eleva Biologics reported a revenue of EUR 50,582.30 and an EBITDA of EUR -6,673,058.10 for 2021. Revenue generation is anchored in strategic partnerships and collaborations with healthcare providers and research institutions, ensuring effective distribution of their innovative therapies.Eleva GmbH plans to expand its product line with new biologic therapies targeting additional orphan diseases within the next two years. The company is also looking to enter new geographic markets, specifically targeting North America and select regions in Asia by 2024. The EUR 60 million raised in January 2021 will be utilized to support these product development initiatives and market expansion efforts.

## Funding rounds

- Series B, Nov 25, 2006, $7.1M — Seed Venture Finance, Gradus Limited, Zukunftsfonds Heilbronn, LEA Partners

## Investors

- Seed Venture Finance (https://capitalatlas.ai/funds/seed-venture-finance) — Series B
- Gradus Limited — Series B
- Zukunftsfonds Heilbronn — Series B
- LEA Partners (https://capitalatlas.ai/funds/lea-partners) — Series B